Smith covers the Healthcare sector, focusing on stocks such as Provention Bio, Keros Therapeutics, and Immunic. According to TipRanks, Smith has an average return of -4.3% and a 39.10% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Provention Bio with a $19.33 average price target, implying a 139.23% upside from current levels. In a report released on November 18, Jefferies also maintained a Buy rating on the stock with a $22.00 price target.
PRVB market cap is currently $704.5M and has a P/E ratio of -5.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
Read More on PRVB: